Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Head and neck squamous cell carcinoma (HNSCC) stands as the prevailing cancer originating within the head and neck area, predominantly influenced by factors such as smoking, excessive alcohol consumption, and human papillomavirus (HPV) infection. Despite treatments, recurrent or metastatic cases of SCCHN typically exhibit a bleak prognosis, with a median survival of around 12 months. Significant advancements have been made in managing recurrent or metastatic SCCHN in recent years. However, outcomes remain subpar, particularly with systemic therapy alone, trailing behind outcomes for other solid tumors. A considerable portion of HNSCC patients facing recurrence or metastasis continue to experience poor survival rates. Consequently, there has been a concentrated effort towards exploring novel biomarkers and therapies based on biomarker analysis. HPV infection has emerged as a primary causal factor for HNSCC, notably in the oropharynx (OPSCC), which accounts for approximately 60–70% of cases in the United States. HPV-positive (HPV+) HNSCC exhibits distinct epidemiological and pathophysiological characteristics compared to HPV-negative (HPV−) counterparts. Typically affecting younger males, HPV+ OPSCC patients are often non-smokers or light smokers, with a mean age of diagnosis in the 40–50s. The onset of HPV+ OPSCC typically occurs after a latency period of 10–30 years following HPV infection.

Thelansis’s “Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033